



# Singh Yudhveer & Associates

## Chartered Accountants

**INDEPENDENT AUDITOR'S REPORT**  
UDIN: 22401054AAAABF4600

**TO THE MEMBERS OF M/S VILIN BIOMED LIMITED**

### **Report on the Standalone Financial Statements**

We have audited the accompanying standalone financial statements of **M/s VILIN BIOMED Limited**, which comprise the Balance Sheet as at March 31, 2021, and the Statement of Profit and Loss (including Other Comprehensive Income), the Statement of Changes in Equity and the Statement of Cash Flows for the year then ended and a summary of the significant accounting policies and other explanatory information.

### **Management's Responsibility for the Standalone Financial Statements**

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance including other comprehensive income, cash flows and changes in equity of the Company in accordance with the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, and other accounting principles generally accepted in India.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.


### **Auditor's Responsibility**

Our responsibility is to express an opinion on these standalone financial statements based on our audit.

In conducting our audit, we have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made there under and the Order issued under section 143(11) of the Act.

We conducted our audit of the standalone financial statements in accordance with the Standards on Auditing specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the standalone financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the standalone financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the standalone financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the standalone financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Company's Directors, as well as evaluating the overall presentation of the standalone financial statements.



UDIN: 22401054AAAABF4600

**ANNEXURE 'A' TO THE INDEPENDENT AUDITOR'S REPORT**

(Referred to in paragraph 1 under 'Report on Other Legal and Regulatory Requirements' section of our report, of even date)

**Report on Companies (Auditor's Report) Order, 2016 ("the Order") issued by the Central Government in terms of Section 143(11) of the Companies Act, 2013 ("the Act") of VILIN BIO-MED LIMITED ("the Company").**

i. In respect of the Company's fixed assets:

(a) The Company has maintained proper records showing full particulars, including quantitative details and situation of fixed assets.

(b) The Company has a program of verification to cover all the items of fixed assets in a phased manner which, in our opinion, is reasonable having regard to the size of the Company and the nature of its assets. Pursuant to the program, certain fixed assets were physically verified by the management during the year. According to the information and explanations given to us, no material discrepancies were noticed on such verification.

(c) According to the information and explanations given to us, the records examined by us and based on the examination of the conveyance deeds provided to us, we report that, the title deeds, comprising all the immovable properties of land and buildings which are freehold, are held in the name of the Company as at the balance sheet date. In respect of immovable properties of land and building that have been taken on lease and disclosed as fixed assets in the standalone financial statements, the lease agreements are in the name of the Company.

ii. As explained to us, the inventories were physically verified during the year by the Management at reasonable intervals and no material discrepancies were noticed on physical verification.

iii. The Company has not granted any loans, secured or unsecured, to companies, firms, limited liability partnerships of other parties covered in the register maintained under Section 189 of the Act.

iv. In our opinion and according to the information and explanations given to us, the Company has complied with the provisions of Sections 185 and 186 of the Act in respect of grant of loans, making investments and providing guarantees and securities, as applicable.


v. The Company has not accepted deposits during the year and does not have any unclaimed deposits as at March 31, 2021 and therefore, the provisions of the clause 3 (v) of the Order are not applicable to the Company.

vi. The maintenance of cost records has not been specified by the Central Government under section 148(1) of the Companies Act, 2013 for the business activities carried out by the Company. Thus, reporting under clause 3(vi) of the order is not applicable to the Company.

vii. According to the information and explanations given to us, in respect of statutory dues: (a) The Company has generally been regular in depositing undisputed statutory dues, including Provident Fund, Employees' State Insurance, Income Tax, Sales Tax, Service Tax, Goods and Service Tax, Value Added Tax, Customs Duty, Excise Duty, Cess and other material statutory dues applicable to it with the appropriate authorities. (b) There were no undisputed amounts payable in respect of Provident Fund, Employees' State Insurance, Income Tax, Sales Tax, Service Tax, Value Added Tax, Goods and Service Tax, Customs Duty, Excise Duty, Cess and other material statutory dues in arrears as at March 31, 2021 for a period of more than six months from the date they became payable.

viii. In our opinion and according to the information and explanations given to us, the Company has not defaulted in the repayment of loans or borrowing to banks. The Company does not have any loans or borrowing from the financial institutions or government and has not issued any debentures.

ix. The Company has not raised moneys by way of initial public offer or further public offer (including debt instruments) or term loans and hence reporting under clause 3 (ix) of the Order is not applicable to the Company.



x. To the best of our knowledge and according to the information and explanations given to us, no fraud by the Company or no material fraud on the Company by its officers or employees has been noticed or reported during the year.

xi. In our opinion and according to the information and explanations given to us, the Company has not paid/provided any managerial remuneration in accordance with the requisite approvals mandated by the provisions of section 197 read with Schedule V to the Act.

xii. The Company is not a Nidhi Company and hence reporting under clause 3 (xii) of the Order is not applicable to the Company.


xiii. In our opinion and according to the information and explanations given to us, the Company is in compliance with Section 177 and 188 of the Companies Act, 2013 where applicable, for all transactions with the related parties and the details of related party transactions have been disclosed in the standalone financial statements as required by the applicable accounting standards.


xiv. During the year, the Company has not made any preferential allotment or private placement of shares or fully or partly paid convertible debentures and hence reporting under clause 3 (xiv) of the Order is not applicable to the Company.

xv. In our opinion and according to the information and explanations given to us, during the year the Company has not entered into any non-cash transactions with its Directors or persons connected to its directors and hence provisions of section 192 of the Companies Act, 2013 are not applicable to the Company.

xvi. The Company is not required to be registered under section 45-1A of the Reserve Bank of India Act, 1934.

For **SINGH YUDHVEER & ASSOCIATES**  
Chartered Accountants  
(Firm Registration No.:011039C)

  
\_\_\_\_\_  
YUDHVEER SINGH  
Proprietor  
(Membership No.: 401054)



Place: Roorkee  
Date: 29-11-2021  
**UDIN: 22401054AAAABF4600**



**VILIN BIO-MED LIMITED**  
 REGD. OFF : H. NO. 6-61-1, 1ST FLOOR, SHILPI COMPLEX, DILSUKHNAGAR  
 HYDERABAD, TELANGANA - 500035  
 WORKS : KH. NO. 85, VILL - MADHOPUR HAZRATPUR, ROORKEE - 247667  
 DISTT - HARIDWAR, UTTARAKHAND  
 CIN :- U24230TG2005PLC046689

**BALANCE SHEET AS AT 31st MARCH 2021**

PARTICULARS		NOTE NO.	AS AT 31st MARCH 2021 (IN RS.)	AS AT 31st MARCH 2020 (IN RS.)
<b>I.</b>	<b>EQUITY AND LIABILITIES</b>			
1	<b>Shareholders' funds</b>			
	(a) Share capital	2	33,000,000.00	33,000,000.00
	(b) Reserves and surplus	3	40,579,472.10	39,368,109.49
2	<b>Share application money pending allotment</b>		-	-
3	<b>Non-current liabilities</b>			
	(a) Long-term borrowings	4	10,157,861.94	-
	(b) Deferred tax liabilities (Net)	-	616,158.71	616,158.71
4	<b>Current liabilities</b>			
	(a) Short-term borrowings	5	45,000,000.00	45,341,186.00
	(b) Trade payables	6	8,168,769.64	18,605,552.25
	(c) Other current liabilities	7	842,167.00	7,478,665.00
	(d) Short-term provisions	8	550,000.00	550,000.00
	<b>TOTAL</b>		<b>138,914,429.39</b>	<b>140,059,671.45</b>
<b>II.</b>	<b>ASSETS</b>			
1	<b>Non-current assets</b>			
	(a) Fixed assets			
	(i) Tangible Assets	9	18,689,298.78	21,260,297.59
	(b) Long-term loans and advances	10	485,213.00	485,213.00
	(c) Other non-current assets		-	-
2	<b>Current assets</b>			
	(a) Inventories	11	20,641,902.00	21,095,978.00
	(b) Trade receivables	12	76,451,594.29	72,693,180.08
	(c) Cash and cash equivalents	13	465,257.00	666,207.84
	(d) Short-term loans and advances	14	22,181,164.32	23,858,794.93
	<b>TOTAL</b>		<b>138,914,429.39</b>	<b>140,059,671.45</b>

FOR & ON BEHALF OF THE BOARD OF DIRECTOR

AS PER OUR SEPARATE REPORT OF EVEN DATE ATTACHED  
 FOR SINGH YUDHVEER & ASSOCIATES  
 CHARTERED ACCOUNTANTS

A. VENUGOPAL  
 Vilin Bio Med Ltd

MG. DIRECTOR  
 DIN-01918868

ANVESH MOOLA

DIRECTOR  
 DIN-08659891

YUDHVEER SINGH  
 PROPRIETOR  
 M. NO. 401054

PLACE: ROORKEE  
 DATE: 29-11-2021  
 UDIN: 22401054AAAAABF4600

*A. Venugopal*

**VILIN BIO-MED LIMITED**  
 REGD. OFF : H. NO. 6-61-1, 1ST FLOOR, SHILPI COMPLEX, DILSUKHNAGAR  
 HYDERABAD, TELANGANA - 500035  
 WORKS : KH. NO. 85, VILL - MADHOPUR HAZRATPUR, ROORKEE - 247667  
 DISTT - HARIDWAR, UTTARAKHAND  
 CIN :- U24230TG2005PLC046689

**STATEMENT OF PROFIT & LOSS FOR THE YEAR ENDED 31st MARCH 2021**

PARTICULARS		NOTE NO.	AS AT 31st MARCH 2021 (IN RS.)	AS AT 31st MARCH 2020 (IN RS.)
I.	Revenue from operations	15	117,152,222.49	168,129,474.19
II.	Other income	16	35,846.76	112,000.00
III.	<b>Total Revenue (I + II)</b>		<b>117,188,069.25</b>	<b>168,241,474.19</b>
IV.	<b>Expenses:</b>			
	Cost of materials consumed	17	90,628,316.57	139,187,848.77
	Change in Inventories of Finished Good, Work In Progress	18	(242,205.00)	(1,964,114.00)
	Employee benefits expense	19	10,612,689.44	13,467,555.74
	Finance costs	20	4,421,070.00	4,050,287.82
	Depreciation and amortization expense	9	2,569,998.82	3,116,340.17
	Other expenses	21	7,586,836.81	8,445,279.65
	<b>Total expenses</b>		<b>115,576,706.64</b>	<b>166,303,198.16</b>
V.	<b>Profit before exceptional and extraordinary items and tax (III-IV)</b>		<b>1,611,362.61</b>	<b>1,938,276.03</b>
VI.	Exceptional items		-	-
VII.	<b>Profit before extraordinary items and tax (V - VI)</b>		<b>1,611,362.61</b>	<b>1,938,276.03</b>
VIII.	Extraordinary Items		-	-
IX.	<b>Profit before tax (VII- VIII)</b>		<b>1,611,362.61</b>	<b>1,938,276.03</b>
X.	Tax expense:			
	(1) Current tax		400,000.00	500,000.00
	(2) Deferred tax		-	-
	(3) Previous Year Tax		-	(138,337.00)
XI.	<b>Profit (Loss) for the period from continuing operations (VII-VIII)</b>		<b>1,211,362.61</b>	<b>1,576,613.03</b>
XII.	Profit/(loss) from discontinuing operations		-	-
XIII.	Tax expense of discontinuing operations/ Income Tax for Earlier Years		-	-
XIV.	<b>Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)</b>		<b>-</b>	<b>-</b>
XV.	<b>Profit (Loss) for the period (XI + XIV)</b>		<b>1,211,362.61</b>	<b>1,576,613.03</b>
XVI.	Earnings per equity share:			
	(1) Basic		0.37	0.48
	(2) Diluted		0.37	0.48

FOR & ON BEHALF OF THE BOARD OF DIRECTOR

AS PER OUR SEPARATE REPORT OF EVEN DATE ATTACHED  
 FOR SINGH YUDHVEER & ASSOCIATES  
 CHARTERED ACCOUNTANTS

Vilin Bio Med Ltd

ANVESH MOOLA

Managing Director

DIRECTOR

REG. DIRECTOR  
 DIN-01918868

DIN-08659891



YUDHVEER SINGH  
 PROPRIETOR  
 M. NO. 401054

PLACE: ROORKEE  
 DATE: 29-11-2021

AUTN: 22401054AAAABF4600

*A. Lal*

**M/S VILIN BIO MED LIMITED**

Regd. Off:H. NO. 6-61-1, 1<sup>ST</sup> FLOOR, SHILPI COMPLEX  
DILSUKHNAGAR, HYDERABAD, TELANGANA -500035  
WORKS:- KH. NO. 85, VILL.- MADHOPUR HAZRATPUR,  
Roorkee-247667 (U.K.)

**Note: 1**

**SIGNIFICANT ACCOUNTING POLICIES:**

**I. Basis of preparation of financial statements**

The financial statements are prepared under the historical cost convention, in accordance with the Indian Generally Accepted Accounting Principles comprising the mandatory accounting standards issued by the Institute of Chartered Accountants of India and the provisions of the Companies Act, 1956/2013 on accrual basis as adopted consistently by the company. All Assets and Liabilities have been classification as current or non-current as per the Company's normal operating cycle and other criteria set out in the revised schedule III of the Companies Act, 2013. For the purpose of current and non-current classification of assets and liabilities, the company has ascertained its operating cycle as 12 months for the purpose of current and non-current classification of assets and liabilities.

**II. System of Accounting**

- i) The company follows the mercantile system of accounting and recognizes income and expenditure on an accrual basis except in case of significant uncertainties.
- ii) Financial statements are based on historical cost. These costs are not adjusted to reflect the impact of changing value in the purchasing power of money.
- iii) Estimates and assumptions used in the preparation of the financial statements and disclosures are based upon management's evaluation of the relevant facts and circumstances as of the date of the financial Statements, which may differ from the actual results at a subsequent date.

**III. Use of Estimates**

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumption that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from these estimates. Adjustments as a result of differences between actual and estimates are prospectively made.

**IV. Revenue Recognition**

**Income**


The Company recognize income (Contractual Receipts) on accrual basis. However, Where the ultimate collection of the same lacks' reasonable certainty, revenue recognition is postponed to the extent of uncertainty.

**V. Fixed Assets:**

Fixed Assets are stated at cost less accumulated depreciation. Cost includes all expenses incurred to bring the assets to its present location and condition.

**VI. Depreciation**

Depreciation (except on land which is not depreciated) is provided as per the provisions of The Companies Act 2013 which requires companies to compute the Depreciation in accordance with the Schedule II to the Companies Act which provides useful lives to compute the Depreciation. Depreciation on additions is pro-rata basis.



Handwritten signatures and initials at the bottom of the page, including a large 'F' and 'J'.


**Opinion**

In our opinion, to the best of our information and according to the explanations given to us, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2021, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For **SINGH YUDHVEER & ASSOCIATES**


Chartered Accountants

(Firm Registration No.:011039C)

  
YUDHVEER SINGH

Proprietor

(Membership No.: 401054)



Place: Roorkee

Date: 29-11-2021

**UDIN: 22401054AAAABF4600**

**Annexure-B to the Independent Auditor's Report of even date on the Financial Statement of M/S VILIN BIOMED LIMITED**

**Report on the Internal Financial Controls Over Financial Reporting under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")**

We have audited the internal financial controls over financial reporting of **M/S VILIN BIOMED LIMITED**, as of March 31, 2021 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

**Management's Responsibility for Internal Financial Controls**

The Board of Directors of the Company is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

**Auditor's Responsibility**

Our responsibility is to express an opinion on the internal financial controls over financial reporting of the Company based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") issued by the Institute of Chartered Accountants of India and the Standards on Auditing prescribed under Section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and events that are necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

**Limitations of Internal Financial Controls Over Financial Reporting**

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.



## VII. Foreign Exchange Transactions

Transactions in foreign currencies are recorded at exchange rates prevailing on the date of the respective transactions. Current assets and current liabilities denominated in foreign currency are translated at the exchange rate prevailing at the date of balance sheet. The resulting difference between the rate prevailing on the date of transaction and on the date of settlement as also on translation of current assets and current liabilities (other than those related to fixed assets where it is adjusted to the cost of acquisition thereof) at the end of the year is recognized at the income or the expense as the case may be.

## VIII. Valuation of Inventories

Inventories are valued at cost or net realizable value whichever is lower. Cost of inventories comprise of all costs of purchase and other cost incurred in bringing the inventory to present location and condition.

## IX. Employee Benefits

The company is not applying Accounting Standard -15. Employee Benefits for future are accounting on cash

## X. Impairment of assets:

In the opinion of the company management there is no impairment to the assets to which accounting standard -28 "Impairment of assets" applied requiring any revenue recognition.

## XI. Borrowing Costs

The company is applying Accounting Standard-16.

As per AS-16, Financing/ Borrowing cost attributable to acquisition and / or construction of qualifying assets is to be capitalized as a part of the cost of such assets up to the date such assets are ready for their intended use. Other financing / Borrowing costs should be charged to profit & loss account.

## XII. Income-Tax

Income Tax expenses comprise of the Current Income Tax, deferred tax charge or credit.

Current Tax is measured at the amount expected to be paid to the tax authorities in accordance with the provisions of Income Tax Act, 1961 as applicable to the financial year.


Deferred Taxes reflects the impact of current year timing differences between taxable income and accounting income for the year and reversal of timing differences of earlier year.

Deferred tax is measured based on the tax laws enacted or substantively enacted at the balance sheet date. Deferred tax recognized only to the extent that there is reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets can be realized.

## XII. Provisions, Contingent Liabilities, and Contingent Assets

A provision is recognized when the company has a present obligation as a result of past event, it is probable that an outflow of resources will be required to settle the obligation, in respect of which a reliable estimate can be made. Provisions are not discounted to its present value and are determined based on best estimate required to settle the obligation at the balance sheet date. These are reviewed at the balance sheet date and adjusted to reflect the current best estimates. Contingent liabilities are not recognized but are disclosed in the notes. Contingent Assets are neither recognized nor disclosed in the financial statements.

\*\*\*\*\*



We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion on the standalone financial statements.

### Opinion

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principle generally accepted in India, of the state of affairs of the Company as at March 31, 2021, and its profit, total comprehensive income, the changes in equity and its cash flows for the year ended on that date.

### Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2016 ("the Order") issued by the Central Government in terms of Section 143(11) of the Act, we give in "Annexure B" a statement on the matters specified in paragraphs 3 and 4 of the Order.

2. As required by Section 143(3) of the Act, based on our audit we report that:

a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.

b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.

c) The Balance Sheet, the Statement of Profit and Loss including Other Comprehensive Income, Statement of Changes in Equity and the Statement of Cash Flow dealt with by this Report are in agreement with the books of account.

d) In our opinion, the aforesaid standalone financial statements comply with the Indian Accounting Standards prescribed under section 133 of the Act.

e) On the basis of the written representations received from the directors of the Company as on March 31, 2021 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2021 from being appointed as a director in terms of Section 164(2) of the Act.

f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure A". Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Company's internal financial controls over financial reporting.

g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended, in our opinion and to the best of our information and according to the explanations given to us:

i. The Company does not have any pending litigations which would impact its financial position.

ii. The Company did not have any long-term contracts including derivatives contracts for which there were any material foreseeable losses.

iii. There were no amounts which required to be transferred by the company to the investors Education and Protection Fund.

For **SINGH YUDHVEER & ASSOCIATES**

Chartered Accountants

(Firm Registration No.: 0110389)

YUDHVEER SINGH


Proprietor

(Membership No.: 401054)

Place: Roorkee

Date: 29-11-2021

UDIN: 22401054AAAABF4600



**VILIN BIO-MED LIMITED**  
 REGD. OFF :H. NO. 6-61-1, 1ST FLOOR, SHILPI COMPLEX, DILSUKHNAGAR  
 HYDERABAD, TELANGANA - 500035  
 WORKS : KH. NO. 85, VILL - MADHOPUR HAZRATPUR, ROORKEE - 247667  
 DISTT - HARIDWAR, UTTARAKHAND  
 CIN :- U24230TG2005PLC046689

NOTE ANNEXED TO AND FORMING PART OF BALANCE SHEET AS AT 31ST MARCH 2021

PARTICULARS	AS AT 1st APRIL 2020 (IN RS.)	ADDITIONS / CREATED DURING THE YEAR	Deductions During the Year	AS AT 31st MARCH 2021(IN RS.)
NOTE NO - 3				
<u>RESERVE &amp; SURPLUS</u> CAPITAL RESERVE ( CAPITAL INVESTMENT SUBSIDY)	2,255,567.00	-	-	2,255,567.00
<b>Total(A)</b>	2,255,567.00	-	-	2,255,567.00
SURPLUS AS PER PROFIT & LOSS ACCOUNT	37,112,542.49	1,211,362.61	-	38,323,905.10
<b>Total(B)</b>	37,112,542.49	1,211,362.61	-	38,323,905.10
<b>Total(A+B)</b>	39,368,109.49	1,211,362.61	-	40,579,472.10



*A. Lal*

*FF*

**VILIN BIO-MED LIMITED**  
 REGD. OFF : H. NO. 6-61-1, 1ST FLOOR, SHILPI COMPLEX, DILSUKHNAGAR  
 HYDERABAD, TELANGANA - 500035  
 WORKS : KH. NO. 85, VILL - MADHOPUR HAZRATPUR, ROORKEE - 247667  
 DISTT - HARIDWAR, UTTARAKHAND

NOTES ANNEXED TO AND FORMING PART OF BALANCE SHEET AS AT 31ST MARCH 2021

PARTICULARS	AS AT 31st MARCH 2021 (IN RS.)	AS AT 31st MARCH 2020 (IN RS.)
<b>NOTE NO. -4</b>		
<b><u>LONG-TERM BORROWINGS</u></b>		
<b><u>SECURED LOAN:-</u></b>		
Loans From Bank	9,226,955.00	
A.N.B. - GECL TL-A/C-389800TL00000270	930,906.94	
A.N.B. - 195 A/C		
Note - Company during the year availed GECL Term Loan which is secured against Govt. guarantee under Covid-19 scheme bearing interest @ 7.65% P.A.		
<b>TOTAL</b>	<b>10,157,861.94</b>	

*A. C. D.*

*Ref*



VILIN BIO-MED LIMITED  
REGD. OFF :H. NO. 6-61-1, 1ST FLOOR, SHILPI COMPLEX, DILSUKHNAGAR  
HYDERABAD, TELANGANA - 500035  
WORKS : KH. NO. 85, VILL - MADHOPUR HAZRATPUR, ROORKEE - 247667  
DISTT - HARIDWAR, UTTARAKHAND

NOTES ANNEXED TO AND FORMING PART OF BALANCE SHEET AS AT 31ST MARCH 2021

PARTICULARS	AS AT 31st MARCH 2021 (IN RS.)	AS AT 31st MARCH 2020 (IN RS.)
<u>NOTE NO. -5</u>  <u>SHORT-TERM BORROWINGS</u> <u>SECURED LOAN:-</u> Loans From Bank P.N.B. Ram Nagar, Roorkee CC- A/c-16831 { Secured against Hypothecation of Stock and Book Debts }	45,000,000.00	45,341,186.00
<b>TOTAL</b>	<b>45,000,000.00</b>	<b>45,341,186.00</b>

A. W. S.

P. S.




**VILIN BIO-MED LIMITED**  
 REGD. OFF :H. NO. 6-61-1, 1ST FLOOR, SHILPI COMPLEX, DILSUKHNAGAR  
 HYDERABAD, TELANGANA - 500035  
 WORKS : KH. NO. 85, VILL - MADHOPUR HAZRATPUR, ROORKEE - 247667  
 DISTT - HARIDWAR, UTTARAKHAND

NOTES ANNEXED TO AND FORMING PART OF BALANCE SHEET AS AT 31ST MARCH 2021

PARTICULARS	AS AT 31st MARCH 2021 (IN RS.)	AS AT 31st MARCH 2020 (IN RS.)
<u>NOTE NO. -6</u>		
<u>TRADE PAYABLE</u> For Purchases & Others	8,168,769.64	18,605,552.25
<b>TOTAL</b>	<b>8,168,769.64</b>	<b>18,605,552.25</b>
<u>NOTE NO. -7</u>		
<u>OTHER CURRENT LIABILITIES</u> Expenses Payable	842,167.00	2,478,665.00
<b>TOTAL</b>	<b>842,167.00</b>	<b>2,478,665.00</b>
<u>NOTE NO. -8</u>		
<u>SHORT TERM PROVISION</u> Provision For Income Tax Provision For Audit Fee	400,000.00 150,000.00	500,000.00 150,000.00
<b>TOTAL</b>	<b>550,000.00</b>	<b>650,000.00</b>

*A. V. V.*

*P. P.*



M/S VILIN BIOMED LIMITED  
 REGD OFF : H.NO. 6-61-1, 1ST FLOOR, SHILPI COMPLEX  
 DILSUKHNAGAR, HYDERABAD, ANDHRA PRADESH - 500035  
 WORKS : K.H. NO. 85, VILL - MADHOPUR HAZRATPUR, ROORKEE - 247667  
 DISTT - HARIDWAR, UTTARAKHAND

STATEMENT OF FIXED (TANGIBLE) ASSETS ANNEXED TO AND FORMING PART OF BALANCE SHEET AS AT 31ST MARCH 2021

Note No. -9

PARTICULARS	GROSS BLOCK					DEPRECIATION			NET BLOCK			
	BALANCE AS ON 01.04.2020	ADDITIONS UP TO 30.09.2020	ADDITIONS AFTER 30.09.2020	SALE/ TRANSFER	TOTAL AS ON 31.03.2021	RATE %	BALANCE AS ON 01.04.2020	FOR THE YEAR	ADJUSTMENT FOR SALE	TOTAL AS ON 31.03.2021	BALANCE AS ON 31.03.2021	BALANCE AS ON 31.03.2020
	LAND	2,115,400.00				2,115,400.00						2,115,400.00
BUILDING	34,899,407.00				34,899,407.00		23,436,556.13	1,77,493.51		24,514,349.54	10,385,357.46	10,462,850.97
FURNITURE & FIXTURE	1,596,291.00				1,596,291.00		1,244,050.99	89,624.98		1,315,711.93	764,579.03	764,579.03
PLANT & MACHINERY	52,942,878.54				52,942,878.54		45,736,353.84	1,06,948.31		47,123,277.93	5,819,600.36	5,819,600.36
COMPUTERS	460,746.00				460,746.00		44,866.79			415,879.21	47,081.00	47,081.00
OFFICE EQUIPMENT	667,857.00				667,857.00		331,831.41	11,620.47		336,216.53	24,155.93	24,155.93
VEHICLE	1,170,875.00				1,170,875.00		1,130,514.48	4,245.33		1,126,629.67	66,124.93	66,124.93
<b>TOTAL (R6.)</b>	<b>93,553,255.14</b>				<b>93,553,255.14</b>		<b>72,192,957.54</b>	<b>2,569,998.82</b>		<b>74,862,956.36</b>	<b>18,689,298.78</b>	<b>21,260,297.60</b>



*Verif*  
*A.*


**VILIN BIO-MED LIMITED**  
 REGD. OFF : H. NO. 6-61-1, 1ST FLOOR, SHILPI COMPLEX, DILSUKHNAGAR  
 HYDERABAD, TELANGANA - 500035  
 WORKS : KH. NO. 85, VILL - MADHOPUR HAZRATPUR, ROORKEE - 247667  
 DISTT - HARIDWAR, UTTARAKHAND

NOTES ANNEXED TO AND FORMING PART OF BALANCE SHEET AS AT 31ST MARCH 2021

PARTICULARS	AS AT 31st MARCH 2021 (IN RS.)	AS AT 31st MARCH 2020 (IN RS.)
<b>NOTE NO. -10</b>		
<b><u>LONG TERM LOAN AND ADVANCE</u></b> Earnest Money & Security	485,213.00	485,213.00
<b>TOTAL</b>	<b>485,213.00</b>	<b>485,213.00</b>
<b>NOTE NO. -11</b>		
<b><u>INVENTORIES</u></b> As taken value certified by the management:		
Raw Materials & Packing Materials	17,865,452.00	18,561,733.00
Semi Finished Good	790,550.00	845,655.00
Finished Good	1,985,900.00	1,688,590.00
<b>TOTAL</b>	<b>20,641,902.00</b>	<b>21,095,978.00</b>
<b>NOTE NO. -12</b>		
<b><u>TRADE RECEIVABLE</u></b> Trade Receivable	76,451,594.29	72,693,180.08
<b>TOTAL</b>	<b>76,451,594.29</b>	<b>72,693,180.08</b>
<b>NOTE NO. -13</b>		
<b><u>CASH AND BANK BALANCES</u></b> Cash In Hand	465,257.00	666,207.84
<b>TOTAL</b>	<b>465,257.00</b>	<b>666,207.84</b>
<b>NOTE NO. -14</b>		
<b><u>SHORT TERM LOAN &amp; ADVANCES</u></b> Sundry Advances GST ITC	12,681,459.32 9,499,705.00	8,179,504.20 15,679,290.73
<b>TOTAL</b>	<b>22,181,164.32</b>	<b>23,858,794.93</b>

A. L. G.

John





**VILIN BIO-MED LIMITED**  
**REGD. OFF :H. NO. 6-61-1, 1ST FLOOR, SHILPI COMPLEX, DILSUKHNAGAR**  
**HYDERABAD, TELANGANA - 500035**  
**WORKS : KH. NO. 85, VILL - MADHOPUR HAZRATPUR, ROORKEE - 247667**  
**DISTT - HARIDWAR, UTTARAKHAND**

**NOTES ANNEXED TO AND FORMING PART OF PROFIT AS AT 31ST MARCH 2021**

PARTICULARS	AS AT 31st MARCH 2021 (IN RS.)	AS AT 31st MARCH 2020 (IN RS.)
<b>NOTE NO. -15</b>		
<b>REVENUE FROM OPERATIONS</b>		
Net Sales	117,152,222.49	168,129,474.19
<b>TOTAL</b>	<b>117,152,222.49</b>	<b>168,129,474.19</b>
<b>NOTE NO. -16</b>		
<b>OTHER INCOME</b>		
Other Income	35,846.76	112,000.00
<b>Total</b>	<b>35,846.76</b>	<b>112,000.00</b>
<b>NOTE NO. -17</b>		
<b>COST OF MATERIAL CONSUMED</b>		
Opening Stock	18,561,733.00	19,462,654.92
Add: Purchase Net	89,932,035.57	138,286,926.85
Less: Closing Stock	17,865,452.00	18,561,733.00
<b>TOTAL</b>	<b>90,628,316.57</b>	<b>139,187,848.77</b>
<b>NOTE NO. -18</b>		
<b>CHANGES IN INVENTORY OF FINISHED GOOD WORK IN PROGRESS AND STOCK IN TRADE</b>		
<b>Increase/ Decrease in Stock</b>		
<b>[A] Closing Stock</b>		
Work In Progress	790,550.00	845,655.00
Finished Good	1,985,900.00	1,688,590.00
<b>TOTAL</b>	<b>2,776,450.00</b>	<b>2,534,245.00</b>
<b>[B] Opening Stock</b>		
Work In Progress	845,655.00	205,425.00
Finished Good	1,688,590.00	364,706.00
<b>TOTAL</b>	<b>2,534,245.00</b>	<b>570,131.00</b>
<b>Net Increase/ (Decrease) [A]-[B]</b>	<b>(242,205.00)</b>	<b>(1,964,114.00)</b>

*A. G. Y.*

*Yaf*



**VILIN BIO-MED LIMITED**  
 REGD. OFF :H. NO. 6-61-1, 1ST FLOOR, SHILPI COMPLEX, DILSUKHNAGAR  
 HYDERABAD, TELANGANA - 500035  
 WORKS : KH. NO. 85, VILL - MADHOPUR HAZRATPUR, ROORKEE - 247667  
 DISTT - HARIDWAR, UTTARAKHAND

**NOTES ANNEXED TO AND FORMING PART OF PROFIT AS AT 31ST MARCH 2021**

PARTICULARS	AS AT 31st MARCH 2021 (IN RS.)	AS AT 31st MARCH 2020 (IN RS.)
<b><u>NOTE NO. -19</u></b>		
<b><u>EMPLOYEE BENEFITS EXPENSES</u></b>		
Salary & Wages	8,436,583.44	11,342,890.00
Directors Remuneration	1,500,000.00	1,500,000.00
Staff Welfare/ Labour Uniform	527,833.00	462,224.00
EPF Administration Charges	6,000.00	10,398.00
EPF Contribution	119,371.00	105,439.00
ESIC Contribution	22,802.00	46,604.74
<b>TOTAL</b>	<b>10,612,689.44</b>	<b>13,467,555.74</b>
<b><u>NOTE NO. -20</u></b>		
<b><u>FINANCE COST</u></b>		
Interest On CC Limit	3,584,065.00	3,801,279.00
Bank Interest (00195)	83,263.00	-
Bank Interest T/L 270A/c	482,479.00	-
Bank Charges	271,263.00	249,008.82
<b>TOTAL</b>	<b>4,421,070.00</b>	<b>4,050,287.82</b>

*A. Uef*

*Uef*



VILIN BIO-MED LIMITED

REGD. OFF :H. NO. 6-61-1, 1ST FLOOR, SHILPI COMPLEX, DILSUKHNAGAR  
HYDERABAD, TELANGANA - 500035  
WORKS : KH. NO. 85, VILL - MADHOPUR HAZRATPUR, ROORKEE - 247667  
DISTT - HARIDWAR, UTTARAKHAND

NOTES ANNEXED TO AND FORMING PART OF PROFIT AS AT 31ST MARCH 2021

PARTICULARS	AS AT 31st MARCH 2021 (IN RS.)	AS AT 31st MARCH 2020 (IN RS.)
<b>NOTE NO. -21</b>		
<b>OTHER EXPENSES</b>		
<b>Manufacturing Exp.:-</b>		
Freight Inward	181,869.63	212,624.87
Consumable Stores	86,363.00	33,130.00
Generator Runing & Maintenance Expenses	554,040.00	617,964.00
Lab Testing Charges	342,830.00	231,290.00
Drug Office Expenses	118,000.00	129,000.00
Power Expenses	1,401,569.38	1,597,908.11
<b>Others:-</b>		
Insurance Charges	14,865.00	81,238.60
Freight Outward	12,220.00	
Miscellaneous Expenses	1,753.00	479,914.80
Printing & Stationary	49,852.00	37,500.00
Office & General Expenses	470,907.96	379,020.20
Postage & Telegram	19,341.00	5,778.00
Professional Fee Expenses	218,000.00	372,000.00
Repairs to Plant & Machinery	570,319.98	406,971.96
Repair & Maintenance Other	440,201.00	356,255.00
Legal Exp.	81,500.00	
Telephone Expenses	63,191.00	53,442.14
Travelling & Conveyance Expenses (Including Director's Travelling)	320,443.00	403,703.00
Security Expenses	670,013.00	642,424.00
Vehicle Running & Maintenance	168,950.00	194,143.00
Rate Diffrence/ Rebate & Discount	1,817,370.00	1,926,096.00
Festival Expenses	3,120.00	99,812.00
Audit Fee	150,000.00	150,000.00
Business Promotion	54,000.00	35,000.00
Short & Excess/ Recovery	(223,882.14)	63.97
<b>TOTAL</b>	<b>7,586,836.81</b>	<b>8,445,279.65</b>

A. L. G.

C.

